ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 785

Longitudinal Angiographic Findings in Patients with Takayasu’s Arteritis

Antoine G. Sreih1, Tanaz A. Kermani2, David Cuthbertson3, Simon Carette4, Lindsy J. Forbess5, Nader A. Khalidi6, Curry L. Koening7, Carol A. McAlear8, Paul A. Monach9, Larry W. Moreland10, Christian Pagnoux11, Philip Seo12, Robert F. Spiera13, Kenneth J. Warrington14, Steven R. Ytterberg14, Carol A. Langford15 and Peter A. Merkel16,17, 1Rheumatology, University of Pennsylvania, Philadelphia, PA, 2Division of Rheumatology, University of California, Los Angeles, CA, 3Biostatistics and Informatics, Department of Pediatrics, University of South Florida, Tampa, FL, 4Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, 5Medicine, Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, 6Rheumatology, McMaster University, Hamilton, ON, Canada, 7Rheumatology, University of Utah, Salt Lake City, UT, 8University of Pennsylvania, Philadelphia, PA, 9Boston University School of Medicine, Boston, MA, 10Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, 11Rheumatology-Vasculitis clinic, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, 12Medicine, Johns Hopkins University, Baltimore, MD, 13Rheumatology, Hospital for Special Surgery, New York, NY, 14Rheumatology, Mayo Clinic, Rochester, MN, 15Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, 16Biostatistics, Epidemiology, and Bioinformatics, University of Pennsylvania, Philadelphia, PA, 17Division of Rheumatology, University of Pennsylvania, Philadelphia, PA

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Angiography, Imaging, large vessel vasculitis, takayasu arteritis and vasculitis

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 5, 2017

Title: Vasculitis Poster I: Large Vessel Vasculitis

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose : Longitudinal data on the type, progression, and predictors of arterial lesions in patients with Takayasu’s arteritis (TAK) is limited. This study aimed to characterize lesions of large arteries in patients with TAK and identify predictors of new lesions.  

Methods: Clinical, laboratory, and imaging data from patients with TAK enrolled in a prospective, multicenter, longitudinal study and/or a randomized clinical trial were included in this study. Lesions were defined as “new or worse” or “improved” arterial aneurysm, stenosis, or occlusion as determined by angiography (83% Magnetic Resonance Angiogram, 23% Computerized Tomography Angiogram, and 4% Conventional Angiogram). Clinical features were defined as the presence of any symptom or sign attributed to vasculitis. Logistic regression was used to analyze the association of baseline (visit 1) variables with new/worse or improved lesions.

Results : The study included 175 patients with TAK: 93% female, 85% Caucasian, mean (±SD) age at diagnosis = 34.4±13.4 years, and mean (±SD) follow-up = 3.8±3.1 years. At baseline, the most frequently affected arteries were subclavian (73% of patients), abdominal aorta (44%), thoracic aorta (42%), and common carotid (37%) (Figure 1). In 123 patients with serial imaging, new or worse arterial lesions were noted in 35 patients (28%) predominantly in the subclavian, common carotid, renal, and iliac territories. 96 % of patients with new lesions were either on prednisone and/or other immunosuppressive agents. Improved stenotic lesions, mostly of the subclavian and common carotid arteries, were noted in 16 patients (13%) at follow-up. Clinical features of active disease were absent in 40% of visits at which a new lesion was detected. The mean levels of erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) did not differ between the immediate prior visit versus the visit at which a new lesion was detected (ESR mean ± SD= 24.6 ± 4.0 and mean CRP ± SD =12.2 ± 2.8 mg/L at prior visit vs. ESR= 23.5 ± 3.9 and CRP= 9.5 ± 2.8 mg/L at lesion visit, p= 0.63 and 0.12 for ESR and CRP respectively). There were no differences in age, sex, ethnicity, presence of a flare prior to the onset of new lesion, or disease duration in patients with or without new/worse lesions and with or without improved lesions.

Conclusion : Among patients with TAK, large arterial abnormalities are common both at presentation and follow-up. One in 3 patients will continue to develop new or worsening arterial lesions while on treatment with 40% exhibiting no clinical or laboratory changes. Lesions involving the subclavian and carotids are more likely to improve during follow-up. These findings raise concerns about the current definition of active disease in TAK and have implications for the management of patients with TAK and the design and conduct of clinical trials in TAK.

Figure 1. Distribution of arterial lesions at baseline and follow-up visits for patients with Takayasu’s arteritis


Disclosure: A. G. Sreih, None; T. A. Kermani, None; D. Cuthbertson, None; S. Carette, None; L. J. Forbess, None; N. A. Khalidi, None; C. L. Koening, None; C. A. McAlear, None; P. A. Monach, Genentech and Biogen IDEC Inc., 2,GlaxoSmithKline, 2,Bristol-Myers Squibb, 2; L. W. Moreland, None; C. Pagnoux, None; P. Seo, GlaxoSmithKline, 5; R. F. Spiera, None; K. J. Warrington, None; S. R. Ytterberg, None; C. A. Langford, None; P. A. Merkel, None.

To cite this abstract in AMA style:

Sreih AG, Kermani TA, Cuthbertson D, Carette S, Forbess LJ, Khalidi NA, Koening CL, McAlear CA, Monach PA, Moreland LW, Pagnoux C, Seo P, Spiera RF, Warrington KJ, Ytterberg SR, Langford CA, Merkel PA. Longitudinal Angiographic Findings in Patients with Takayasu’s Arteritis [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/longitudinal-angiographic-findings-in-patients-with-takayasus-arteritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/longitudinal-angiographic-findings-in-patients-with-takayasus-arteritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology